SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Report abuse about a comment

Sponsors involved as well

One should not forget that CROs still work for sponsors and do not conduct trials for themselves. The fact that sales outside the US have grown that much demonstrates that the big pharma , which is by far the biggest client of global CROs, is more and more interested in selling its products outside the US market. This is particularly true for emerging countries such as Brasil or India. And since it is way easier to get registration and to sell its drug, in Brasil for example, once trials have been conducted in the country, sponsors ask for CROs to have an international expansion. Therefore it is not only the CROs that are globalising, it is the whole pharma industry.

Posted by Guillaume Miara
30 August 2011 | 15h30

Please fill in the box below to tell us why you feel the post breaks our rules. When you are finished, click on "Send" so that it can be reviewed by a moderator.

Your name *
Your email *

We will not publish your email on the site

Reason *

Back to: Over 50% of sales at top CROs now made outside US; report

Spotlight

Public CROs are sign of booming market, not PE apathy say experts
News focus

Public CROs are sign of booming market, not PE apathy say financial advisors

Experts have predicted more CROs will go public as Private Equity looks to get a return on...

Biologics trials: the ‘stretched’ global supply chain

Biologics trials: the ‘stretched’ global supply chain

The high cost and complexity of producing biopharmaceuticals for clinical trials limits supplies and makes effective logistics...

Charles River to lay off up to 30 employees following NCI contract end

Charles River to lay off up to 30 employees following NCI contract termination

Early phase CRO (contract research organization) Charles River Laboratories will lay off between 26 and 30 employees...

Pharma firms ‘saving billions’ in research – by giving away their tech

Pharma firms ‘saving billions’ in research – by giving away their tech

Pharma’s biggest players have donated more than $102m ($78m) of technology in a project to transform data...

CMO Kentucky Bioprocessing grows Ebola mAb from tobacco

CMO Kentucky Bioprocessing grows Ebola mAb from tobacco

ZMapp, the experimental Ebola therapy given to a handful of infected patients in West Africa, is being...

CRO Crown: Advancing in vitro models could benefit preclinical world

Crown Bio: New in vitro technology could revolutionise drug discovery

Increasing the predictivity of in vitro systems could cut the costs of drug development and shift preclinical...

Key Industry Events

 

Access all events listing

Our events, Events from partners...